Moneycontrol PRO

Buy Dabur India: target of Rs 675: Sharekhan

Sharekhan is bullish on Dabur India has recommended buy rating on the stock with a target price of Rs 675 in its research report dated May 06, 2021.

June 10, 2021 / 11:14 AM IST
An Edelweiss research report for Q4FY21 says road tonnage continued to improve, evident in e-way bill generation (up 6% QoQ) and improved core trucking rentals. “We estimate tonnage would increase by three–five percent for truckers. Asset-light plays Mahindra Logistics and TCI Express remain our preferred picks due to their ability to scale up/down as the environment demands,” the report said. Edelweiss is bullish on Blue Dart Express due to the pandemic-induced boom in e-commerce and its leaner cost structure. It has retained a ‘buy’ call on Mahindra Logistics, TCI Express and Blue Dart Express.

An Edelweiss research report for Q4FY21 says road tonnage continued to improve, evident in e-way bill generation (up 6% QoQ) and improved core trucking rentals. “We estimate tonnage would increase by three–five percent for truckers. Asset-light plays Mahindra Logistics and TCI Express remain our preferred picks due to their ability to scale up/down as the environment demands,” the report said. Edelweiss is bullish on Blue Dart Express due to the pandemic-induced boom in e-commerce and its leaner cost structure. It has retained a ‘buy’ call on Mahindra Logistics, TCI Express and Blue Dart Express.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sharekhan's research report on Dabur India


Dabur India Limited’s (Dabur) domestic volume growth stood at 25% in Q4FY2021, lower than our as well street’s expectation of 30%-35%. OPM stood flat at 18.9%; PAT grew by 27% to Rs. 377.9 crore (lower than street expectation of Rs. 425 crore). CRS implementation resulted in inventory correction due to lesser pre-season stocking up with distributors, leading to lower revenue by ~Rs. 100 crore-120 crore. Q4 is seasonally a soft quarter for winter-related healthcare products (including Chyawanprash), leading to lower growth. Supply-led disruption might affect near-term performance. Health supplements and ethical regaining momentum, discretionary categories to see moderation.


Outlook


We have reduced our estimates for FY2022 by 7%, while we have fine-tuned them for FY2023. We maintain Buy with a PT of Rs. 675.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 27, 2021 12:47 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark